vs

Side-by-side financial comparison of CareDx, Inc. (CDNA) and Quest Resource Holding Corp (QRHC). Click either name above to swap in a different company.

CareDx, Inc. is the larger business by last-quarter revenue ($117.7M vs $58.9M, roughly 2.0× Quest Resource Holding Corp). CareDx, Inc. runs the higher net margin — 2.4% vs -2.8%, a 5.2% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs -15.8%). Quest Resource Holding Corp produced more free cash flow last quarter ($1.0M vs $514.0K). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs -10.0%).

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

Quest Resource Holding Corp provides end-to-end waste management, recycling, and sustainability solutions to commercial, industrial, and retail clients across North America. It helps businesses cut waste volumes, reduce operational costs, and fulfill corporate environmental targets via customized waste diversion and circular economy initiatives.

CDNA vs QRHC — Head-to-Head

Bigger by revenue
CDNA
CDNA
2.0× larger
CDNA
$117.7M
$58.9M
QRHC
Growing faster (revenue YoY)
CDNA
CDNA
+54.8% gap
CDNA
39.0%
-15.8%
QRHC
Higher net margin
CDNA
CDNA
5.2% more per $
CDNA
2.4%
-2.8%
QRHC
More free cash flow
QRHC
QRHC
$492.0K more FCF
QRHC
$1.0M
$514.0K
CDNA
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
-10.0%
QRHC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CDNA
CDNA
QRHC
QRHC
Revenue
$117.7M
$58.9M
Net Profit
$2.8M
$-1.7M
Gross Margin
15.5%
Operating Margin
1.0%
0.9%
Net Margin
2.4%
-2.8%
Revenue YoY
39.0%
-15.8%
Net Profit YoY
82.6%
EPS (diluted)
$0.05
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDNA
CDNA
QRHC
QRHC
Q1 26
$117.7M
Q4 25
$108.4M
$58.9M
Q3 25
$100.1M
$63.3M
Q2 25
$86.7M
$59.5M
Q1 25
$84.7M
$68.4M
Q4 24
$86.6M
$70.0M
Q3 24
$82.9M
$72.8M
Q2 24
$92.3M
$73.1M
Net Profit
CDNA
CDNA
QRHC
QRHC
Q1 26
$2.8M
Q4 25
$-4.1M
$-1.7M
Q3 25
$1.7M
$-1.3M
Q2 25
$-8.6M
$-2.0M
Q1 25
$-10.4M
$-10.4M
Q4 24
$87.7M
$-9.5M
Q3 24
$-10.6M
$-3.4M
Q2 24
$-4.6M
$-1.5M
Gross Margin
CDNA
CDNA
QRHC
QRHC
Q1 26
Q4 25
15.5%
Q3 25
18.1%
Q2 25
18.5%
Q1 25
16.0%
Q4 24
15.3%
Q3 24
16.1%
Q2 24
18.5%
Operating Margin
CDNA
CDNA
QRHC
QRHC
Q1 26
1.0%
Q4 25
-5.6%
0.9%
Q3 25
-0.2%
1.7%
Q2 25
-12.8%
0.6%
Q1 25
-15.8%
-11.9%
Q4 24
97.5%
-10.3%
Q3 24
-16.6%
-1.3%
Q2 24
-7.9%
2.4%
Net Margin
CDNA
CDNA
QRHC
QRHC
Q1 26
2.4%
Q4 25
-3.8%
-2.8%
Q3 25
1.7%
-2.1%
Q2 25
-9.9%
-3.3%
Q1 25
-12.2%
-15.2%
Q4 24
101.3%
-13.6%
Q3 24
-12.8%
-4.7%
Q2 24
-5.0%
-2.1%
EPS (diluted)
CDNA
CDNA
QRHC
QRHC
Q1 26
$0.05
Q4 25
$-0.08
$-0.08
Q3 25
$0.03
$-0.06
Q2 25
$-0.16
$-0.09
Q1 25
$-0.19
$-0.50
Q4 24
$1.60
$-0.47
Q3 24
$-0.20
$-0.16
Q2 24
$-0.09
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDNA
CDNA
QRHC
QRHC
Cash + ST InvestmentsLiquidity on hand
$77.9M
$1.0M
Total DebtLower is stronger
$64.0M
Stockholders' EquityBook value
$40.5M
Total Assets
$411.1M
$145.6M
Debt / EquityLower = less leverage
1.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDNA
CDNA
QRHC
QRHC
Q1 26
$77.9M
Q4 25
$177.2M
$1.0M
Q3 25
$194.2M
$1.1M
Q2 25
$186.3M
$449.0K
Q1 25
$230.9M
$1.4M
Q4 24
$260.7M
$396.0K
Q3 24
$240.9M
$1.1M
Q2 24
$228.9M
$957.5K
Total Debt
CDNA
CDNA
QRHC
QRHC
Q1 26
Q4 25
$64.0M
Q3 25
$65.4M
Q2 25
$69.7M
Q1 25
$74.1M
Q4 24
$76.3M
Q3 24
$0
$71.9M
Q2 24
$0
$70.7M
Stockholders' Equity
CDNA
CDNA
QRHC
QRHC
Q1 26
Q4 25
$303.1M
$40.5M
Q3 25
$311.1M
$42.0M
Q2 25
$327.4M
$42.9M
Q1 25
$379.3M
$44.4M
Q4 24
$378.4M
$54.2M
Q3 24
$273.2M
$62.8M
Q2 24
$264.7M
$65.6M
Total Assets
CDNA
CDNA
QRHC
QRHC
Q1 26
$411.1M
Q4 25
$413.2M
$145.6M
Q3 25
$432.3M
$149.3M
Q2 25
$444.3M
$153.1M
Q1 25
$489.6M
$165.7M
Q4 24
$491.1M
$175.6M
Q3 24
$477.0M
$178.2M
Q2 24
$466.8M
$181.8M
Debt / Equity
CDNA
CDNA
QRHC
QRHC
Q1 26
Q4 25
1.58×
Q3 25
1.56×
Q2 25
1.62×
Q1 25
1.67×
Q4 24
1.41×
Q3 24
0.00×
1.15×
Q2 24
0.00×
1.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDNA
CDNA
QRHC
QRHC
Operating Cash FlowLast quarter
$4.3M
$1.1M
Free Cash FlowOCF − Capex
$514.0K
$1.0M
FCF MarginFCF / Revenue
0.4%
1.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$9.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDNA
CDNA
QRHC
QRHC
Q1 26
$4.3M
Q4 25
$21.4M
$1.1M
Q3 25
$37.4M
$5.7M
Q2 25
$9.9M
$3.9M
Q1 25
$-26.6M
$-1.1M
Q4 24
$21.9M
$-4.8M
Q3 24
$12.5M
$-475.0K
Q2 24
$18.9M
$808.0K
Free Cash Flow
CDNA
CDNA
QRHC
QRHC
Q1 26
$514.0K
Q4 25
$1.0M
Q3 25
$5.6M
Q2 25
$3.9M
Q1 25
$-1.2M
Q4 24
$-5.2M
Q3 24
$-583.0K
Q2 24
$-1.4M
FCF Margin
CDNA
CDNA
QRHC
QRHC
Q1 26
0.4%
Q4 25
1.7%
Q3 25
8.9%
Q2 25
6.5%
Q1 25
-1.8%
Q4 24
-7.4%
Q3 24
-0.8%
Q2 24
-2.0%
Capex Intensity
CDNA
CDNA
QRHC
QRHC
Q1 26
Q4 25
0.1%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.2%
Q4 24
0.6%
Q3 24
0.1%
Q2 24
3.1%
Cash Conversion
CDNA
CDNA
QRHC
QRHC
Q1 26
1.54×
Q4 25
Q3 25
22.30×
Q2 25
Q1 25
Q4 24
0.25×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

QRHC
QRHC

Services$55.8M95%
Product Sales And Other$3.1M5%

Related Comparisons